Bioatla, INC Form 4 insider transactions

BioAtla CFO Christian Vasquez reported the withholding of common stock shares to satisfy tax obligations following the vesting of restricted stock units.

BioAtla's Chief Medical Officer, Eric Sievers, was granted 240,000 restricted stock units, increasing his beneficial ownership to 598,705 shares.

BioAtla, Inc. CEO Jay M. Short, PhD, was granted 430,000 restricted stock units, aligning executive incentives with long-term shareholder value.

BioAtla CEO Jay M. Short's recent Form 4 filing details the withholding of 7,728 common shares by the issuer to cover tax obligations related to vested restricted stock units.

BioAtla's Chief Financial Officer, Christian Vasquez, reported a routine disposition of 1,802 common shares for tax withholding purposes related to vested restricted stock units.

BioAtla's former CFO, Richard A. Waldron, had 2,729 shares withheld for tax obligations related to restricted stock unit vesting.

BioAtla's Chief Medical Officer, Eric Sievers, reported a tax-related disposition of 3,140 common shares following the vesting of restricted stock units.

BioAtla's CFO, Richard A. Waldron, reported a routine withholding of 2,371 common shares for tax obligations tied to restricted stock unit vesting.

BioAtla's Chief Medical Officer, Eric Sievers, had 2,729 shares withheld by the company to cover tax obligations related to the vesting of restricted stock units.

BioAtla's CEO, Jay M. Short, reported a routine withholding of 6,347 common shares by the issuer to cover tax obligations related to restricted stock unit vesting.

BioAtla officer Christian Vasquez reported a tax-related disposition of 1,566 common shares at $0.904, retaining 291,998 shares.

BioAtla's CEO, Jay M. Short, reported a routine transaction involving shares withheld for tax obligations related to vested restricted stock units.

BioAtla's Chief Accounting Officer, Christian Vasquez, had 1,566 shares withheld by the company to cover tax obligations from restricted stock unit vesting.

BioAtla's Chief Medical Officer, Eric Sievers, had 2,729 shares withheld by the company to cover tax obligations related to restricted stock unit vesting.

BioAtla's Chief Financial Officer, Richard A. Waldron, had 2,371 shares withheld by the company to cover tax obligations related to restricted stock unit vesting.

BioAtla, Inc. Director Susan Moran was granted 23,500 shares of common stock through a restricted stock unit award, increasing her beneficial ownership to 52,307 shares.

BioAtla, Inc. Director Eddie Williams was granted 23,500 shares of common stock in the form of restricted stock units, increasing his beneficial ownership to 60,200 shares.

BioAtla, Inc. Director Lawrence Steinman was granted 23,500 shares of common stock in the form of a time-based restricted stock unit award on June 18, 2025, increasing his beneficial ownership to 78,459 shares.

BioAtla, Inc. Director Mary Ann Gray was granted 23,500 shares of common stock in the form of a time-based restricted stock unit award, vesting in 2026 or at the next annual meeting.

BioAtla, Inc. Director Sylvia McBrinn was granted 23,500 shares of common stock through a time-based restricted stock unit award, increasing her beneficial ownership to 59,125 shares.

BioAtla, Inc. Director Scott Andrew Smith was granted 23,500 shares of common stock in the form of a time-based restricted stock unit award, vesting in 2026 or at the next annual meeting.

BioAtla, Inc.'s Chief Accounting Officer, Corporate Controller, and Secretary, Christian Vasquez, reported a routine transaction involving the withholding of 1,566 shares of common stock for tax purposes related to restricted stock unit vesting.

BioAtla, Inc.'s Chief Executive Officer and 10% owner, Jay M. Short, PhD, reported the withholding of 6,347 shares of common stock by the issuer to cover tax obligations related to the vesting of restricted stock units.

BioAtla's Chief Medical Officer, Eric Sievers, had 2,729 shares of common stock withheld by the company to cover tax obligations related to the vesting of previously reported restricted stock units.

BioAtla, Inc.'s Chief Financial Officer, Richard A. Waldron, reported the disposition of 2,371 common shares to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units.

Christian Vasquez, Chief Accounting Officer, Corporate Controller, and Secretary of BioAtla, Inc., acquired 85,000 shares of common stock through a restricted stock unit (RSU) award on March 11, 2025.

BioAtla's CEO, Jay M. Short, acquired 431,000 shares of common stock through a restricted stock unit (RSU) award, as reported in a recent SEC filing.

Richard Waldron, CFO of BioAtla, Inc., acquired 100,000 shares of common stock through a restricted stock unit (RSU) award that vests over time.

Eric Sievers, Chief Medical Officer of BioAtla, Inc., acquired 175,000 shares of common stock through a restricted stock unit award.

BioAtla's CEO, Jay M. Short, reports the withholding of shares to cover income tax obligations related to the vesting of restricted stock units.